A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
← catalyst calendarNCT07207369 · readout ≤ 1,199 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
395estimated
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-24 | actual | When the study began enrolling |
| Primary completion | Nov 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acne Scars
Interventions
- Device: ELAPR002f Injectable Gel
- Device: Saline Control
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants who Achieve a 20% Reduction in Acne Scar Area
measured Baseline to Day 181
Number of Participants with Adverse Events
measured Up to Day 420
Number of Participants with Presence of Binding Antibodies
measured Up to Day 420
Number of Participants with Injection Site Responses (ISRs) and Systemic Responses
measured Up to Day 420
Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters
measured Up to Day 420
Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters
measured Up to Day 420
Number of Participants With Clinically Significant Changes From Baseline in Physical Measurements
measured Up to Day 420
Change from Baseline Procedure Pain
measured Up to Day 420
Number of Participants with a Positive Skin Test
measured Up to Day 420
Number of Participants with Visual Disturbance Symptoms Associated with Vascular Occlusion
measured Up to Day 420
Number of Participants Needing a Histology of Volar Forearm Site Biopsy
measured Up to Day 420
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed